The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

​Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the

10 Overlooked Growth Stocks to Buy Now. ​Telix Pharmaceuticals Limited (NASDAQ:TLX) is one of the overlooked growth stocks to buy now. On April 14, Telix Pharmaceuticals announced the dosing of the first patient in its pivotal Phase 3 IPAX-BrIGHT trial. This marks a historic milestone as the first radiopharmaceutical therapy to reach Phase 3 development for recurrent glioblastoma, a highly aggressive and difficult-to-treat form of brain cancer. The trial is evaluating the safety and efficacy of TLX101-Tx (¹³¹I-iodofalan) in combination with the chemotherapy drug lomustine, compared to chemotherapy alone. The treatment uses a novel small-molecule approach to target the L-type amino acid transporter 1 (LAT1). Because LAT1 is overexpressed in glioblastoma cells, the radiopharmaceutical can successfully cross the blood-brain barrier to deliver targeted radiation directly to the tumor site. This mechanism is particularly significant given that only two drugs have been FDA-approved for glioblastoma in the last 25 years, and there is currently no established standard of care for patients once the disease recurs. The Phase 3 study builds on encouraging data from earlier trials, such as IPAX-1, which showed a median overall survival of 13 months from the start of treatment. In the IPAX-BrIGHT trial, Telix’s companion PET imaging agent, TLX101-Px, will be used to select eligible patients and monitor their metabolic response to the therapy. With regulatory approvals already secured in Australia and several European nations, ​Telix Pharmaceuticals Limited (NASDAQ:TLX) aims for this registration-enabling study to establish a first-in-class therapy for a patient population with very limited options.

​Telix Pharmaceuticals Limited (NASDAQ:TLX) is a biopharma company that specializes in therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. The company develops clinical and commercial-stage products to address unmet medical needs in oncology and rare diseases. While we acknowledge the potential of TLX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. Disclosure: None. Follow Insider Monkey on Google News.